相关临床试验
31
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1924
进行中（未招募）
1
3.2%
已完成
21
67.7%
Enrolling By Invitation
1
3.2%
尚未招募
2
6.5%
招募中
1
3.2%
暂停
1
3.2%
终止
2
6.5%
撤回
2
6.5%
暂无批准数据
- Shanghai Ark Biopharmaceutical received FDA clearance for its Investigational New Drug application for AK3280, enabling a Phase 2 proof-of-concept trial in idiopathic pulmonary fibrosis patients. - The multi-center, randomized, partially double-blind trial will evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 compared to placebo and active controls. - Previous Phase 2 results in China showed AK3280 demonstrated statistically significant, dose-dependent improvements in forced vital capacity at Week 24 with favorable safety profile. - The drug addresses significant unmet medical needs in IPF, where current therapies have limited clinical benefit and are associated with gastrointestinal adverse events affecting patient adherence.
- Researchers at The Scripps Research Institute have developed diAcCA, a stable derivative of carnosic acid found in rosemary and sage, which enhanced memory and brain density in mouse models of Alzheimer's disease. - The compound significantly increased synaptic connections and reduced amyloid plaques and tau tangles in treated mice, with memory function reportedly improving "virtually back to normal" according to lead researcher Stuart Lipton. - DiAcCA works by combating inflammation and oxidative stress, achieving 20% higher blood levels than natural carnosic acid, and was well-tolerated in the three-month preclinical study.
